The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
Abstract
Background: Sunitinib inhibits KIT and other members of the split‐kinase‐domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib‐resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. Procedure: Sunitinib therapy was provided through a treatment‐use protocol. Patients were 10–17 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6‐week treatment cycles. KIT and platelet‐derived growth factor receptor alpha (PDGFRA) genotyping of tumor tissue were performed. Results: One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1–2. None of the five patients tested had mutations in KIT or PDGFRA. Conclusion: Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib‐resistant GIST. Pediatr Blood Cancer 2009;52:767–771. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citation
Cited by
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Self-citationGastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3143 · Cited by 891
Self-citationCasali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy095 · Cited by 750
Gastrointestinal stromal tumour
Joensuu, H., Hohenberger, P., & Corless, C. L. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60106-3 · Cited by 703
Janeway, K. A., Kim, S. Y., Lodish, M., Nosé, V., Rustin, P., Gaal, J., Dahia, P. L. M., Liegl, B., Ball, E. R., Raygada, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009199108 · Cited by 628
Self-citation
Metadata
- Authors
- Janeway, K. A., Albritton, K. H., Van Den Abbeele, A. D., D'Amato, G. Z., Pedrazzoli, P., Siena, S., Picus, J., Butrynski, J. E., Schlemmer, M., Heinrich, M. C., & Demetri, G. D.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2009-03-26
- Volume
- 52
- Issue
- 7
- Pages
- 767-771
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W1975011523
- Cited by
- 162
- References
- 1
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. https://app.cochat.ai/papers/10.1002/pbc.21909
- The paper
- Janeway, K. A., Albritton, K. H., Van Den Abbeele, A. D., D'Amato, G. Z., Pedrazzoli, P., Siena, S., Picus, J., Butrynski, J. E., Schlemmer, M., Heinrich, M. C., & Demetri, G. D. (2009). Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.21909
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.